




RealRate

PHARMACEUTICAL 2019

Ernexa Therapeutics Inc
Rank 193 of 361



The relative strengths and weaknesses of Ernexa Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Ernexa Therapeutics Inc compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 113% points. The greatest weakness of Ernexa Therapeutics Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 157% points.

The company's Economic Capital Ratio, given in the ranking table, is 253%, being 3.1% points above the market average of 250%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	6,785	Assets	14,864
Cost of Goods Sold	0	Liabilities	7,947
Intangible Assets	667	Expenses	23,068
Liabilities, Current	4,024	Revenues	23,335
Liabilities, Non-Current	0	Stockholders Equity	6,917
Other Assets	2,745	Net Income	-259
Other Compr. Net Income	-145	Comprehensive Net Income	-332
Other Expenses	8,582	BaseVar	34,942
Other Liabilities	3,923	ECR before LimitedLiability	129%
Other Net Income	-526	Economic Capital Ratio	253%
Other Revenues	23,335		
Property and Equipment	4,667		
Research and Development	0		
Selling, General and Administrative Expense	14,486		